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Abstract 
CD2AP gene encodes for an adaptor protein with 
high homology to Cin85. It was originally cloned as 
CD2 interacting protein and, in an independent 
study, as p130-Cas interacting protein. It contains 
three SH3 domains, a proline-rich motif and a 
coiled-coil domain that allow it to form complexes 
with numerous proteins and to participate in 
different physiological processes. Several evidences 
suggest that it links cell surface proteins and 
specialized junctions with the actin cytoskeleton and 
that it regulates the assembly of actin filaments to 
guide cell shape and movements. 
Notably, CD2AP plays a crucial role in the 
glomerular cells differentiation and in the 
maintenance of the kidney filtration barrier, and 
CD2AP-deficient mice die of renal failure before the 
age of six weeks. Mutations resulting in a lower 
expression of CD2AP were found in FSGS kidney 
disease patients. It is also involved in neuronal 
disorders and two single nucleotide polymorphisms 
of the gene have been associated with increased risk 
of Alzheimer' s disease. Finally, although the protein 
is expressed in the majority of the cell types, it was 
proposed as optimal marker for BPDCN 
hematological malignancy. 
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CD2AP associated protein (:14258) 
Location 
6p12.3. The gene is located on Chromosome 6, starts 
at 47477746 according to NCBI (47477789 
according to ensembl) and ends at 47627263 . 
Local order 
CD2AP gene is surrounded by LOC105375082 on 
the 5' end and ADGRF2 on the 3' end (NCBI 2017, 
Aug 2017). Two pseudogenes (LOC100421517 and 
RPS12P14) overlap with it. 
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Chromosomal location of human CD2AP gene, according to NCBI. CD2AP gene is located on Chromosome 6, 
starting at 47477746 and ending at 47627263. The gene orientation is on the plus strand. 
DNA/RNA 
 
The longest transcript of CD2AP gene. It is 5412 bases long and consists of eighteen exons (represented as 
vertical bars) divided by 17 introns (represented as lines). Two short non coding regions at 5' and 3' complete the 
transcript. The length of each exon is reported (in number of bases). 
 
Description 
The human CD2AP gene is located on chromosome 
6p12, it is 149.517 bps long and comprises 18 exons 
(NCBI Gene ID: 23607, 2017) 
Transcription 
The longest transcript is 5412 bases long, and 
comprises 18 exons. This transcript codes for the full 
lenght protein; four short transcripts (less than 700 
bases) have been reported, but their functional role is 
unknown (Ensemble, Aug 2017). Two of these non-





Schematic representation of the CD2AP protein. Three SH3 domains occupy the amino terminal region of the 
protein (aa 1-330), followed by a short proline-rich motif (336-422). The carboxyl-terminal region contains an 
actin capping protein (CP) binding motif and a coiled-coil region (577-638) (Dikic 2002, Bruck et al. 2006). 
 
Description 
CD2AP protein is an adaptor protein composed of 
several regions with binding functions: three SH3 
domains, one proline rich region, four actin binding 
domains, AP-2 and CP binding motifs and a coiled-
coil region. The protein is 639 aminoacids long and 
has a predicted molecular weight of 71,451 Dalton. 
The SH3 domains are located at the amino terminus 
of the protein and mediate complexes formation. 
Actually, SH3 domains are short modules of 60 
amino acids commonly involved in the assembly and 
regulation of signalling processes by recognizing 
polyproline motifs, shaped in a left-handed type II 
helix, on the surface of the target proteins. In 
particular, CD2AP SH3 domains selectively 
recognize polyproline regions containing the 
consensus PXXXPR. One of this motif is contained 
in the p53 trascription factor, only in one of the two 
p53 polymorphic variants P72R, and allows the 
adaptor protein to selectively bind the 72 R variant 
(Panni et al. 2015). The crystal structure of two of 
the SH3 domains of CD2AP have been solved, 
showing that the domains conserve the typical beta-
barrel shape, with five beta strands (Moncalian et 
al.2006; Yao et al. 2007). Two AP-2 binding motif 
(FXDXFX) overlap with the first and third SH3 
domains respectively, while a third motif lies 
between the second and the third SH3 (Brett et al. 
2002). Beyond these domains, the proline rich region 
(aa 336-422) contains motifs recognized by the SH3 
domains of p130Cas, Src, Fyn, Yes and PI3K, all 
proteins involved in signal transduction (Kirsch et al. 
1999, Dikic 2002). The presence of four putative 
actin binding sites (aa 534-538; 599-603; 610-614; 
631-635) was observed in (Kirsch et al. 1999; Dikic 
2002) and the direct binding of CD2AP to actin was 
shown in (Lehtonen et al. 2002), while the in vivo 
colocalization and co-immunoprecipitation of 
CD2AP with actin was demonstrated in (Yuan et al. 
2002; Gaidos et al. 2007). Instead a CP (actin 
barbed-end capping protein) binding motif is present 
CD2AP (CD2 associated protein)  
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at amino acids 486-502 and mediates the binding of 
CD2AP to CP (which in turn binds to actin) and the 
resulting inhibition of the protective function of CP 
on actin filaments (Bruck et al. 2006; Takeda et al. 
2010). The Carboxyl-terminal region adopts a 
coiled-coil conformation that allows the protein to 
homodimerise or heterodimerise with the homolog 
Cin85. (Kirsch et al. 1999, Gaidos et al. 2007) 
Expression 
CD2AP mRNA is ubiquitously expressed in human 
tissues (Kirsch et al. 1999). In particular, it is 
strongly expressed in the placenta, colon, kidney, 
pancreas and thymus, while a lower expression was 
detected in aorta, skeletal muscle, bladder and uterus 
(Kirsch et al. 1999). 
Localisation 
CD2AP protein is localised mainly to the plasma 
membrane and to the cytosol 
 
CD2AP Interaction Network. The network was downloaded from the Intact Database (except for 
some nodes that were manually added) and visualized with Cytoscape (Orchard et al. 2014; Shannon 
et al. 2003). Both direct interactions and indirect associations of CD2AP are shown. 
 
Function 
The presence of binding domains allows CD2AP to 
control the assembly of multiprotein complexes and 
to transmit signals involved in different biological 
processes. The protein was first identified as p130-
Cas interactor (and named CMS as "Cas ligand with 
Multiple SH3") and its colocalization with p130-Cas 
and F-actin strongly suggested for a function in the 
regulation of the actin cytoskeleton as an adaptor 
protein (Kirsch et al. 1999). This role was largely 
confirmed by subsequent observations: in normal 
cells, monomeric actin (G actin) polymerises in 
filaments (F actin) that bind to CD2AP (Gaidos et al. 
2007); in podocytes the absence of CD2AP causes a 
dramatic defect due to the loss of their specialised 
actin-rich foot processes that operate the filtration in 
kidney (Shih et al 1999 ; Gaidos et al. 2007). It was 
further shown that to guarantee stability to the actin 
polymer, its barbed ends are in complex with the 
actin-capping protein CP that avoid the addiction 
and the loss of monomers. In the presence of 
CD2AP, CP is prevented to bind actin filaments 
barbed end, and actin filaments can be extended or 
shortened (Bruck et al. 2006). Notably, CD2AP is 
required to recruit CP to the cell periphery during 
lamellipodia formation (Zhao et al. 2013) and to 
regulate actin accumulation at the adherens junctions 
(Tang and Brieher 2013). An independent work 
identified mouse CD2AP as CD2 receptor clustering 
activator in the specialized junctions between T cells 
and antigen-presenting cells (Dustin et al. 1998). 
This interaction also connects surface receptors to 
the actin cytoscheleton. A similar model was 
proposed in Drosophila, where Cindr, the CD2AP 
homolog, was shown to link cell-cell adhesion 
junctions with actin cytoscheleton by binding to E-
Cadherin and IgCAM Roughest (Johnson et al. 2008; 
Johnson et al. 2012). It was also observed that upon 
CD2AP (CD2 associated protein)  
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(7) 288 
 
EGF treatment CBL associates to CD2AP that 
recruits it to membrane ruffles where they both 
colocalize (Kirsch et al. 2001; Lynch et al. 2003), 
linking endocytosis to actin polymerization. RAC1 
was found in membrane ruffles in complex with 
CTTN (cortactin) and CD2AP (Van Dujin et al. 
2011). Recently it was suggested that the adaptor 
protein may anchor a fraction of the 72R variant of 
the TP53 protein in the cytosol, connecting it with 
membrane receptors and actin cytoscheleton (Panni 
et al. 2015). All these observations suggest for a role 
of CD2AP in regulating membrane proteins and 
specialized cell junctions and to connect them with 
actin cytoscheleton dynamics. 
 
The sequence alignment of the two homolog human proteins CD2AP and Cin85. The SH3 domains are 
highlighted in yellow and the proline-rich in green. Pink letters indicate the CP binding motif and the Coiled-
Coil region. AP2 binding motifs are underlined and positions annotated as potential missense or nonsense 
mutations in Cosmic database (Forbes et al. 2017) are represented by red letters. 
 
Homology 
CD2AP is a member of the Cin85/CMS family of 
adaptor proteins which comprises two paralogs: 
CD2AP (CMS) and Cin85 (Figure 5) . They are 
conserved among mammalian species, but not in C. 
elegans and yeast. The D. melanogaster homolog, 
Cindr, only share 30% of homology with CD2AP 
(Blast Alignment tool 
https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Mutations 
101 missense substitutions plus 8 nonsense 
substitutions mapping in the coding region of 
CD2AP gene have been annotated in the Cosmic 
Database (Forbes et al. 2017) from tumorigenic 
tissues analysis (positions involved are shown as red 
letters in Figure 5) , however none of them has been 
clearly associated with the tumorigenic tissue 
analysed.  Mutation R612STOP was also found in 
one patient affected from focal segmental 
glomerulosclerosis (FSGS, see below) and it was 
shown that the mutation impairs gene expression 
(Lowik et al. 2007). 32 synonymous mutations have 
also been reported in Cosmic (not shown in the 
figure).  
 
Two mutations of the splicing acceptor site of exon 
seven, that result in a lower expression of the gene, 
have been reported from FSGS patients (Kim et al. 
2003). 
Implicated in 
CD2AP gene is clearly implicated in Focal 
Segmental Glomerulosclerosis, and its 
polymorphisms have been associated with 
Alzheimer Disease. Instead, although it was shown 
to interact with many proteins involved in signal 
transduction and with p53, its involvement in the 
development of cancer is not well documented. 
According to data provided by Human Protein Atlas 
and obtained with antibodies against CD2AP, the 
protein is strongly expressed in pancreatic, gastric, 
colorectal, prostate, breast, ovarian and urothelial 
cancers and in it is used as a prognostic marker in 
pancreatic cancer and urothelial cancer. It is a marker 
for plasmacytoid dendritic cell neoplasm too (see 
below).  
 
CD2AP (CD2 associated protein)  
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It has been proposed as a promising target for ErbB2 
overexpressing tumors since it participates in the 
inhibition of activated ErbB2 (Mineghishi et al. 
2013). 
Focal Segmental Glomerulosclerosis 
Mice CD2AP-/- die by 6-7 weeks of age for severe 
kidney pathology and proteinuria. In particular they 
showed glomerular injury with loss of podocyte foot 
processes and slit diaphragm integrity and with 
extracellular deposits of fibronectin and collagen 
(Shih et al. 1999). At molecular level, CD2AP 
immunoprecipitates with nephrin, the major 
component of the slit diaphragm (Shih et al. 1999 ; 
Shih et al. 2001), suggesting that the pathology arises 
from a deregulation of actin polymerisation in foot 
processes and loss of connection between nephrin 
and the actin cytoscheleton. Mice with CD2AP 
haploinsufficiency develop glomerular defects 
similar to the human focal segmental 
glomerulosclerosis disease, and in human patients 
mutations in CD2AP coding sequence or in the 
splicing regulatory regions were associated with the 
pathology (Kim et al. 2003; Lowik et al. 2007; Chen 
& Liapis, 2015) 
Disease 
Focal Segmental Glomerulosclerosis (FSGS) is a 
progressive glomerular disease characterized by 
localised sclerotic lesions (only some of the 
glomeruli are involved and only a part of them is 
affected) and podocyte loss.  Glomerulus is a 
specialized apparatus to filter blood in kidney and 
the filtration barrier is constituted by endothelial 
cells, glomerular basement membrane and foot 
processes called podocytes (Shih et al. 1999). In 
FSGS patients, non functional podocytes are 
detached from the glomerular basement membrane 
which results in severe nephrosis with proteinuria 
and glomerulosclerosis (Nagata et al, 2017). 
Extracellular deposits of collagens and other fibrous 
proteins are also observed in affected glomeruli. 
30% of all nephrotic syndromes in adults are due to 
FSGS with elevated costs to health care (Nagata et 
al. 2017). 
Alzheimer Disease 
CD2AP polymorphisms were found associated with 
late onset Alzheimer's disease (LOAD, see below) in 
two genome-wide association studies (Hollingworth 
et al. 2011; Naj et al. 2011). In particular, SNPs 
rs9296559 and rs9349407 were found associated 
with increased LOAD risk. Very little is known 
about how the protein may affect the AD risk and 
what function it exerts in brain. Its role in vescicular 
transport to the lysosome and in the formation of 
synapses may be relevant to its involvment (Karch & 
Goate, 2015). It was recently shown that CD2AP 
knock-down mice have a compromised blood-brain 
barrier with increased permeability, and the function 
of CD2AP in maintaining blood barrier integrity was 
proposed to be related with the higher predisposition 
to the disease (Cochran et al. 2015). It was also 
shown that the deletion of CD2AP determine a 
decrease in Aβ levels (Liao et al. 2015). 
Disease 
The Alzheimer's Disease (AD) is a complex 
multifactorial neuronal disease characterized by 
extensive neuronal loss due to extracellular 
deposition of beta amyloid plaques (Aβ) and 
intracellular development of neurofibrillary tangles 
(NTF). AD is classified in late-onset AD (LOAD), 
that occurs in elderly people and is one of the most 
common cause of dementia, and early-onset AD 
(EOAD) when the disease occurs in young people 
(Rosenthal and Kamboh  et al. 2014). 
Blastic Plasmacytoid Dendritic Cell 
Neoplasm (BPDCN) 
CD2AP has been proposed as a specific marker to 
diagnostic BPDCN among other hematological 
neoplastic disorders because it is expressed at high 
level in both normal and transformed pDC cells. The 
molecular diagnosis of myeloproliferative disorders 
is based on markers such as CD4 or CD56 that are 
expressed in different cell types. Instead CD2AP, 
unless it was originally cloned in T cells, was shown 
to strongly react to specific antibodies only in pDC 
cells, suggesting that it may represent an interesting 
marker for pDC derived malignancies  (Marafioti et 
al. 2008; Rizvi et al. 2012). 
Disease 
Blastic Plasmacytoid dendritic cell neoplasm 
(BPDCN) is a rare hematological malignancy 
involving plasmacytoid dendritic cells (pDC), that 
was classified in 2008 under acute myeloid leukemia 
(Riaz et al. 2014). It represents only 0.44% of the 
hematological malignancies however patients have 
poor outcomes, with median survival ranging from 
12 to 16 months. Most patients present cutaneous 
lesions, while bone marrow, peripheral blood and 
lymph nodes are also involved (Riaz et al. 2014). 
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